Literature DB >> 30275085

Nitazoxanide Is a Therapeutic Option for Adenovirus-Related Enteritis in Immunocompromised Adults.

Zerelda Esquer Garrigos1, Dylan Barth1, Ahmed M Hamdi1, Omar M Abu Saleh1, M Rizwan Sohail2.   

Abstract

Entities:  

Keywords:  adenovirus; enteritis; immunocompromised; nitazoxanide

Mesh：

Substances：

Year:  2018        PMID： 30275085      PMCID： PMC6256758          DOI： 10.1128/AAC.01937-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  3 in total

1.  The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation.

Authors:  Menashe Elazar; Michael Liu; Sean A McKenna; Ping Liu; Elizabeth A Gehrig; Joseph D Puglisi; Jean-François Rossignol; Jeffrey S Glenn
Journal:  Gastroenterology       Date:  2009-08-04       Impact factor: 22.682

2.  Nitazoxanide Inhibits Human Norovirus Replication and Synergizes with Ribavirin by Activation of Cellular Antiviral Response.

Authors:  Lei Xu; Buyun Ma; Wen Dang; Sunrui Chen; Yuebang Yin; Kyeong-Ok Chang; Maikel P Peppelenbosch; Qiuwei Pan
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

Review 3.  Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus.

Authors:  Jean-François Rossignol
Journal:  J Infect Public Health       Date:  2016-04-16       Impact factor: 3.718
  3 in total
  2 in total

Review 1.  Epigenetics and the dynamics of chromatin during adenovirus infections.

Authors:  Kelsey L Lynch; Linda R Gooding; Charlie Garnett-Benson; David A Ornelles; Daphne C Avgousti
Journal:  FEBS Lett       Date:  2019-12-15       Impact factor: 4.124

Review 2.  Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?

Authors:  Dina B Mahmoud; Zayyanu Shitu; Ahmed Mostafa
Journal:  J Genet Eng Biotechnol       Date:  2020-07-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.